Zobrazeno 1 - 10
of 182
pro vyhledávání: ''
Autor:
Dinja T. Kruger, Karin Beelen, Vincent van der Noort, Sabine C. Linn, Joyce Sanders, Epie Boven, Mark Opdam, Bart de Valk, Michiel Nieuwenhuis
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Kruger, D T, Opdam, M, van der Noort, V, Sanders, J, Nieuwenhuis, M, de Valk, B, Beelen, K J, Linn, S C & Boven, E 2020, ' PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane ', Journal of Cancer Research and Clinical Oncology, vol. 146, no. 11, pp. 3013-3023 . https://doi.org/10.1007/s00432-020-03291-x
Journal of Cancer Research and Clinical Oncology, 146(11), 3013-3023. Springer Verlag
Kruger, D T, Opdam, M, van der Noort, V, Sanders, J, Nieuwenhuis, M, de Valk, B, Beelen, K J, Linn, S C & Boven, E 2020, ' PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane ', Journal of Cancer Research and Clinical Oncology, vol. 146, no. 11, pp. 3013-3023 . https://doi.org/10.1007/s00432-020-03291-x
Journal of Cancer Research and Clinical Oncology, 146(11), 3013-3023. Springer Verlag
Purpose Everolimus plus exemestane (EVE/EXE) is a registered treatment option for ER-positive, HER2-negative (ER +/HER2-) metastatic breast cancer (MBC), but resistance mechanisms limit efficacy. We aimed to find markers that might help select patien
Autor:
Tongtong Wei, Kai Liang, Yingxing Pan, Li Li, Jinjing Song, Cuifang Teng, Jie Yang, Mo Xiaoxiang, Naiquan Mao, Guolin Huang, Min Luo
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 146:2519-2534
Metastasis is an unavoidable event happened among almost all small cell lung cancer (SCLC) patients. However, the molecular driven factors have not been elucidated. Recently, a novel hydrolase called cell migration inducing hyaluronidase (CEMIP) trig
Autor:
Boris Duchemann, Jean-Baptiste Assié, Kader Chouahnia, Gaetan Des Guetz, Thierry Landre, Christos Chouaid
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 146:3333-3339
Erlotinib is indicated as first-line treatment for patients with non-small-cell lung cancer (NSCLC) harboring an epidermal growth-factor–receptor (EGFR) mutation. Addition of a vascular endothelial growth factor (VEGF) inhibitor (anti-VEGF) in comb
Autor:
Vittorio Branchi, Adrian Georg Simon, Marieta Toma, Manuel Ritter, Glen Kristiansen, Jörg Ellinger, Stefan C. Müller, Thomas Mayr, Yuri Tolkach, Michael Muders, Laura Esser
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 146:2255-2265
To investigate the synergistic effect of glycolysis inhibition on therapy answer to tyrosine kinase inhibitors in renal carcinoma. Primary cell cultures from 33 renal tumors including clear cell RCC (ccRCC), papillary RCC and the rare subtype chromop
Autor:
Gemma Bruera, Ioannis Papasotiriou, Giammaria Fiorentini, Donatella Sarti, Enrico Ricevuto, Andrew R. Mackay, Francesco Masedu, Paola Palumbo, Marco Clementi, Marco Valenti, Stefano Guadagni, Panagiotis Apostolou, Aldo Victor Giordano
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Background Hepatic artery infusion (HAI) and drug selection by liquid biopsy precision oncotherapy are under investigation for the multidisciplinary treatment of unresectable colorectal liver metastases (CRCLM) in progression after systemic therapy.
Autor:
Marcus Vetter, Kerstin Hoeck, Michael Friedlander, Siti Omar, Andreas Schoetzau, Neville F. Hacker, André B. Kind, Viola Heinzelmann-Schwarz, Kenneth J. Russell, Daniel Fink
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Background Malignant mixed Mullerian tumors of endometrial (MMMT-E) and ovarian (MMMT-O) origin are associated with poor prognosis. Suggestively epithelial-driven tumors, their treatment has shifted from anthracycline or ifosfamide-based towards taxa
Autor:
Sheida Nabavi, Panagiotis A. Konstantinopoulos, Charles J. Murphy, Gerburg M. Wulf, Julia Eismann, Ioannis S. Vlachos, Ursula A. Matulonis, Yujing J. Heng, Kathryn P. Gray, Johannes M. Waldschmidt
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose Fusion genes can be therapeutically relevant if they result in constitutive activation of oncogenes or repression of tumor suppressors. However, the prevalence and role of fusion genes in female cancers remain largely unexplored. Here, we inv
Autor:
Tabea Quecke, Nikolas von Bubnoff, Piet Zamzow, Corinna Steidel, Annika Freund, Frank Gieseler, Fanny Ender
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose The expression of active tissue factor (TF) on the surface of microvesicles (MVs) is essential for the activation of the coagulation system and transduction of the signaling pathways in cancer cells. In its use as a biomarker for cancer-assoc
Autor:
Inken Hilgendorf, Maximilian Fleischmann, Karin G. Schrenk, Florian Prims, Jochen J. Frietsch, Christian Thiede, Jakob Hammersen, Sebastian Scholl, Ulf Schnetzke, Andreas Hochhaus
Publikováno v:
Journal of cancer research and clinical oncology. 148(11)
Background Diagnosis of acute myeloid leukemia (AML) is associated with poor outcome in elderly and unfit patients. Recently, approval of the BCL-2 inhibitor venetoclax (VEN) in combination with hypo-methylating agents (HMA) led to a significant impr
Autor:
Xiaoming Chen, Song Chen, Xu Bo, Huanwei Chen, Wenquan Zhuang, Liguang Wang, Zhiqiang Wu, Qicong Mai, Wenbo Guo, Fan Wang, Feng Shi, Jiaming Lai
Publikováno v:
Journal of cancer research and clinical oncology. 148(8)
Purpose The aim of this retrospective study was to compare the clinical outcomes of pembrolizumab-lenvatinib-transarterial chemoembolization (TACE) versus lenvatinib-TACE sequential therapy in selected populations of Chinese patients with initially u